Synthesis 2011(23): 3827-3838  
DOI: 10.1055/s-0030-1260260
PAPER
© Georg Thieme Verlag Stuttgart ˙ New York

Asymmetric Syntheses of S,S-Dialkyl-Substituted Sulfoximines and Related Heterocycles

Ankur G. Pandey, Matthew J. McGrath, Olga García Mancheño, Carsten Bolm*
Institute of Organic Chemistry, RWTH Aachen University, Landoltweg 1, 52056 Aachen, Germany
Fax: +49(241)8092391; e-Mail: Carsten.Bolm@oc.rwth-aachen.de;
Further Information

Publication History

Received 30 August 2011
Publication Date:
17 October 2011 (online)

Abstract

Enantiomerically enriched forms of a sulfoximine-based myristic acid analogue are prepared using either an asymmetric desymmetrization with a chiral base, or an enantioselective oxidation procedure as key steps. Additionally, a variety of 2-oxa-2-alkyl 3,4-dihydro 2,1-benzothiazines are synthesized via intramolecular metal­-catalyzed N-arylation of appropriately functionalized sulfoximines with tethered 2-bromoaryl substituents. In turn, the sulfoximines are prepared by lithiation-alkylation sequences including enantioselective deprotonation steps or the use of an optically active sulfoxide. Using this methodology, the range of accessible 3,4-dihydro 2,1-benzothiazine derivatives is expanded.

    References

  • For reviews, see:
  • 1a Reggelin M. Zur C. Synthesis  2000,  1 
  • 1b Harmata M. Chemtracts  2003,  16:  660 
  • 1c Okamura H. Bolm C. Chem. Lett.  2004,  33:  482 
  • 1d Bolm C. In Asymmetric Synthesis with Chemical and Biological Methods   Enders D. Jaeger K.-E. Wiley-VCH; Weinheim: 2007.  p.149 
  • 1e Worch C. Mayer AC. Bolm C. In Organosulfur Chemistry in Asymmetric Synthesis   Toru T. Bolm C. Wiley-VCH; Weinheim: 2008.  p.209 
  • 1f Bentley R. Chem. Soc. Rev.  2005,  34:  609 
  • 2 For recent patents involving sulfoximines, see references 3 and 4 in: García Mancheño O. Dallimore J. Plant A. Bolm C. Adv. Synth. Catal.  2010,  352:  309 
  • 3a Bentley HR. McDermott EE. Pace J. Whitehead JK. Moran T. Nature  1950,  165:  150 
  • 3b Bentley HR. McDermott EE. Whitehead JK. Nature  1950,  165:  735 
  • 4 For a key publication in this area, see: Brandt J. Gais H.-J. Tetrahedron: Asymmetry  1997,  8:  909 
  • For early reports on the inhibitory activity of methionine sulfoximine, see:
  • 5a Pace J. McDermott EE. Nature  1952,  169:  415 
  • 5b Meister A. Science  1983,  220:  472 
  • From these and subsequent studies it is known that for this particular dialkyl sulfoximine the (S,S)-diastereoisomer is the most active.
  • 6 For a recent example, where a mixture of stereoisomers of buthionine sulfoximine (BSO) was used to study induced apoptotic cell death, see: Takahashi K. Tatsunami R. Oba T. Tampo Y. Biol. Pharm. Bull.  2010,  33:  556 
  • 7 McDonald IA. Nyce PL. Ku GS. Bowlin TL. Bioorg. Med. Chem. Lett.  1993,  3:  1717 
  • 8 Jackson TE. inventors; (Sandoz-Wander, Inc., USA) US Patent  4031227.  ; Chem. Abstr. 1977, 87, 102318
  • 9 McGrath MJ. Bolm C. Beilstein J. Org. Chem.  2007,  3:  33 
  • 10a Kagan HB. Dunach E. Nemecek C. Pitchen P. Samuel O. Zhao S.-H. Pure Appl. Chem.  1985,  1911 
  • 10b Capozzi MAM. Cardellicchio C. Naso F. Tortorella P. J. Org. Chem.  2000,  65:  2843 
  • 10c For a review, see: Capozzi MAM. Cardellicchio C. Naso F. Eur. J. Org. Chem.  2004,  1855 
  • For syntheses of structurally related 2,1-benzothiazine and 1,2-benzoisothiazole derivatives by alternative pathways, see:
  • 11a Harmata M. Kahraman M. J. Org. Chem.  1998,  63:  6845 
  • 11b Harmata M. Pavri N. Angew. Chem. Int. Ed.  1999,  38:  2419 
  • 11c Hong X. Harmata M. J. Am. Chem. Soc.  2003,  125:  5754 
  • 11d Harmata M. Rayanil K.-o. Gomes MG. Zheng P. Calkins NL. Kim S.-Y. Fan Y. Bumbu V. Lee DR. Wacharasindhu S. Hong X. Org. Lett.  2005,  7:  143 
  • 11e Harmata M. Calkins NL. Baughman RG. Barnes CL. J. Org. Chem.  2006,  71:  3650 
  • 11f Harmata M. Chen Y. Barnes CL. Org. Lett.  2007,  9:  4701 
  • 11g Harmata M. Ying W. Hong X. Barnes CL. Synthesis  2008,  594 
  • 11h Harmata M. Rayanil K.-o. Espejo VR. Barnes CL. J. Org. Chem.  2009,  74:  3214 
  • 11i Harmata M. Cai Z. Chen Y. J. Org. Chem.  2009,  74:  5559 
  • 11j For a review, see: Harmata M. Hong X. Prog. Heterocycl. Chem.  2008,  19:  1 
  • 12 For the synthesis of isomeric dihydro benzothiazines by intramolecular α-arylation of sulfoximines, see: Bolm C. Okamura H. Verrucci M. J. Organomet. Chem.  2003,  687:  444 
  • 13 For the possible precision of such data, see: Wernerova M. Hudlicky T. Synlett  2010,  2701 
  • 14a García Mancheño O. Dallimore J. Plant A. Bolm C. Org. Lett.  2009,  11:  2429 
  • 14b

    See also reference 2.

  • 15 Taylor S. Gullick J. McMorn P. Bethell D. Page PCB. Hancock EF. King F. Hutchings GJ. Top. Catal.  2003,  24:  43 
  • 16a For pioneering work on the use of the nosyl group, see: Fukuyama T. Jow C.-K. Cheung M. Tetrahedron Lett.  1995,  36:  6373 
  • 16b Here the N-nosyl deprotection was performed following procedures reported in: Greene TW. Wuts PGM. Protective Groups in Organic Synthesis   3rd ed.:  John Wiley & Sons; New York: 1999.  p.603 
  • 17 Johnson CR. Kirchoff RA. Reischer RJ. Katekar GF. J. Am. Chem. Soc.  1973,  95:  4287 
  • 18a N-Cyano sulfoximine 7d was prepared following reported procedures, see: García Mancheño O. Bistri O. Bolm C. Org. Lett.  2007,  9:  3809 
  • 18b See also in: Pandey A. Bolm C. Synthesis  2010,  2922 
  • 19a Bolm C. Hildebrand JP. Tetrahedron Lett.  1998,  39:  5731 
  • 19b Bolm C. Hildebrand JP. J. Org. Chem.  2000,  65:  169 
  • 19c Bolm C. Hildebrand JP. Rudolph J. Synthesis  2000,  911 
  • 19d Bolm C. Martin M. Gibson L. Synlett  2002,  832 
  • See also:
  • 19e Harmata M. Hong X. Ghosh SK. Tetrahedron Lett.  2004,  45:  5233 
  • 19f Harmata M. Hong X. Synlett  2007,  969 
  • 20a Bolm C. Sedelmeier J. J. Org. Chem.  2005,  70:  6904 
  • 20b For a related copper-mediated N-arylation, see: Cho G.-Y. Rémy P. Jansson J. Moessner C. Bolm C. Org. Lett.  2004,  6:  3293 
  • For the synthesis of tert-butylthiosulfinate, see:
  • 22a Weix DJ. Ellman JA. Org. Lett.  2003,  5:  1317 
  • 22b Blum SA. Bergman RG. Ellman JA. J. Org. Chem.  2003,  68:  150 
  • 22c Cogan DA. Liu G. Kim K. Backes BJ. Ellman JA. J. Am. Chem. Soc.  1998,  120:  8011 
  • 22d Liu G. Cogan DA. Ellman JA. J. Am. Chem. Soc.  1997,  119:  9913 
  • 22e Weix DJ. Ellman JA. Org. Synth.  2005,  82:  157 
  • 24a García Mancheño O. Bolm C. Org. Lett.  2006,  8:  2349 
  • 24b See also: García Mancheño O. Bolm C. Chem. Eur. J.  2007,  13:  6674 
21

The relative configuration of diastereoisomeric 4-methyl substituted benzothiazines 9b and 9b′ was assigned by comparison with the NMR patterns of reported 4-alkyl substituted analogues (see reference 11a). Accordingly, the relative configuration of their precursors 8b and 8b′ was also established.

23

The enantiomeric ratio of 19 was determined by HPLC: Daicel Chiralpack AS, heptane-i-PrOH, 97:3, 0.9 mL˙min, 254 nm, t R1 = 6.3 min, t R2 = 7.7 min.

25

The absolute configuration of 7e could be deduced by considering that the nucleophilic substitution of 19 proceeded with inversion of configuration and that the imination occurred under retention. For respective details, see references 22 and 24.